Andarix appoints experts to help in the development of P2045

08/1/2011 | PR Web

Andarix Pharmaceuticals has appointed new clinical oncology experts to its clinical advisory board to help with the development of its lead drug candidate, P2045. The drug is a treatment for lung and other cancers and is based on a radiolabeled somatostatin peptide analogue.

View Full Article in:

PR Web

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA